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a b s t r a c t
Objectives: The objectives were to compare the long-term outcomes, including hysterectomy, chronic pelvic pain
(CPP) and abnormal uterine bleeding (AUB), in women post hysteroscopic sterilization (HS) and laparoscopic
tubal ligation (TL) in the Medicaid population.
Study design: This was a retrospective observational cohort analysis using data from the US Medicaid Analytic
Extracts Encounters database. Women aged 18 to 49 years with at least one claim for HS (n=3929) or TL (n=
10,875) between July 1, 2009, through December 31, 2010, were included. Main outcome measures were
hysterectomy, CPP or AUB in the 24 months poststerilization. Propensity score matching was used to control
for patient demographics and baseline characteristics. Logistic regression analysis investigated the variables
associated with a 24-month rate of each outcome in the HS versus laparoscopic TL cohorts.
Results: Postmatching analyses were performed at 6, 12 and 24 months post index procedure. At 24 months,
hysterectomy was more common in the laparoscopic TL than the HS group (3.5% vs. 2.1%; p=.0023), as was
diagnosis of CPP (26.8% vs. 23.5%; p=.0050). No signiﬁcant differences in AUB diagnoses were observed. Logistic
regression identiﬁ ed HS as being associated with lower risk of hysterectomy (odds ratio [OR] 0.77 [95%
conﬁdence interval {CI} 0.60–0.97]; p=.0274) and lower risk of CPP diagnosis (OR 0.91 [95% CI 0.83–0.99]; p=
.0336) at 24 months poststerilization.
Conclusion: In Medicaid patients, HS is associated with a signiﬁcantly lower risk of hysterectomy or CPP diagnosis
24 months poststerilization versus laparoscopic TL. Incidence of AUB poststerilization is not signiﬁcantly
different. While some differences in outcomes were statistically signiﬁcant, the effect sizes were small, and the
conclusion is one of equivalence and not clinical superiority.
Implications statement: This propensity score matching analysis conﬁrms that pelvic pain and AUB are common in
women before and after sterilization regardless of whether the procedure is performed hysteroscopically or
laparoscopically. Moreover, HS is associated with a signiﬁcantly lower risk of hysterectomy or a CPP diagnosis
in the 24 months poststerilization when compared to TL.
© 2018 Elsevier Inc. All rights reserved.

1. Introduction
Although trends suggest a declining rate of female sterilization in the
United States [1], it remains the second most common form of contraception among US reproductive-aged women [2]. Methods available
☆ Capsule: In the Medicaid population, hysteroscopic sterilization is associated with a
lower risk of hysterectomy and chronic pelvic pain compared to tubal ligation, with a
similar incidence of abnormal uterine bleeding.
⁎ Corresponding author. Tel.: +1 862 404 5154.
E-mail addresses: rsteward@allcare-med.com (R. Steward),
Patricia.Carney@bayer.com (P. Carney), Amy.Law@bayer.com (A. Law),

for interval sterilization (sterilization at a time remote from delivery)
include laparoscopic tubal ligation (TL) and hysteroscopic sterilization
(HS). TL requires entry into the peritoneal cavity and general anesthesia,
whereas HS involves an implant being placed into the fallopian tubes
through a hysteroscope.
In an analysis of a large commercial insurance database, women who
underwent HS had a higher rate of menstrual dysfunction but a lower
rate of hysterectomy and pelvic pain 1 to 5 years postprocedure compared to women who had laparoscopic TL [3]. Another study of the
same database showed that during a 12-month follow-up, women
who underwent HS versus TL had the same incidence of opioidmanaged pelvic pain [4]. Finally, while not comparative, a retrospective
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managed pelvic pain [4]. Finally, while not comparative, a retrospective
cohort study found that women who have preexisting pain conditions
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(chronic headache, low back pain, pelvic pain, and ﬁbromyalgia) are 6
times as likely to experience both acute and chronic pelvic pain (CPP)
following the Essure hysteroscopic tubal sterilization procedure [5].
Women with no or public insurance are more likely to undergo sterilization than women with commercial insurance. African American
race, less education and poverty also increase the likelihood of sterilization [1,6] . Current data on sequelae after sterilization are limited to
women with commercial insurance [3], and it is unknown whether
the same outcomes can be expected in a population of women who
are publicly insured.
The current study was undertaken to compare the rate of hysterectomy and the diagnosis of CPP or abnormal uterine bleeding (AUB), outcomes also explored by Perkins et al., in the 24 months after sterilization
by laparoscopic TL or HS in women who were covered by Medicaid.
2. Materials and methods
2.1. Data source
This retrospective, observational cohort study used data from the US
Medicaid Analytic Extracts (MAX) Encounters database, which contains
individual-level information on characteristics of Medicaid enrollees.
This database includes demographic data (e.g., age, race), information
on dispensed prescription drugs identiﬁed by a National Drug Code,
Medicaid services (e.g. physician services, laboratory/x-ray, clinical services, premium payments, outpatient hospital claims), institutional
long-term care services and inpatient services (including diagnoses,
procedures, discharge status, length of stay and payment amount). In
compliance with the Health Insurance Portability and Accountability
Act of 1996, the database comprises fully deidentiﬁed data sets. Therefore, this study was exempt from Institutional Review Board overview
under the Common Rule (45 CFR x46.101(b) [4]).
2.2. Subjects
Women aged 18 to 49 years who had at least one claim for HS (Current Procedural Terminology [CPT] code: 58565) or interval laparoscopic TL (CPT codes: 58670 or 58671) at any time during July 1, 2009,
through December 31, 2010 (Supplementary Fig. 1), were included in
this study. The date of the claim for the sterilization procedure was deﬁned as the index date. The study included only women who had
6 months of continuous medical and pharmacy claims data prior to
the procedure and at least 24 months after the procedure. The entire
study period, including baseline and follow-up, was January 1, 2009,
through December 31, 2012. At the time of the analysis, 35 states
were available in the 2012 MAX data.
Patients were excluded from the analysis if they underwent postpartum TL during the study period; had already undergone a sterilization
procedure during the baseline period; had a claim for pregnancy or delivery within 6 weeks before the index date; had more than one type of
sterilization procedure on the index date; had concurrent procedures on
the same day as the index sterilization procedure that may have an impact on the study outcomes (Supplementary Table 1); or had a modiﬁer
-53 next to the procedure code on the index date, indicating an incomplete procedure.
All available data that met the inclusion and exclusion criteria were
included.
2.3. Analysis and outcomes

429

(ICD-9) diagnostic codes for pelvic pain/lower abdominal pain and
AUB (Supplementary Table 2).
Poststerilization CPP was deﬁned as receiving ≥2 diagnoses of pelvic
pain/lower abdominal pain on at least 2 separate visits, beginning
2 weeks post index procedure. At least one of these diagnoses had to
be received at least 3 months after the index procedure (indicating
some degree of chronicity). AUB was deﬁned as ≥2 diagnoses of AUB
at least 2 weeks post index procedure with at least one of them occurring beyond 3 months after the index procedure.
2.4. Statistical analysis
All baseline and outcome variables were analyzed descriptively. Percentages and numbers were calculated for dichotomous and polychotomous variables, and compared using chi-square test with p values and
95% conﬁdence intervals (CIs). Means with SDs were calculated for continuous variables and compared using t tests, with p values and 95% CI.
In addition, standardized differences (effect size [ES]), deﬁned as the absolute difference in sample means divided by an estimate of the pooled
SD of the variable, were calculated for each variable. Standardized differences were reported as 100 times the absolute ES difference.
Patient matching was carried out in two steps by the combination of
exact match of patient characteristics and propensity score matching
(PSM). Exact patient match ensured that the matched patient groups
have the same distribution of key baseline patient characteristics (as
identiﬁed by DeNoble et al. in their study of medical comorbidities common in reproductive aged women), and included baseline pain status
(as identiﬁed by Yunker et al. in their study of pelvic pain post Essure
placement) and the presence of baseline AUB diagnosis codes [5,7]. History of pain was not included in the propensity score as it would provide
a good match rather than an exact match. Baseline pain and baseline
AUB are considered strong confounders that are important to be
matched exactly [5,7]. PSM was then conducted within each of the stratiﬁed groups, and additional patient demographic and clinical characteristics were controlled in the PSM that enabled the matched populations
to have the same and/or similar baseline characteristics. Multivariable
logistic regression analysis was carried out on the entire unmatched
sample as a sensitivity analysis to check on the robustness of the ﬁndings from the matching analysis. Multivariable logistic regression was
used to generate the propensity score, with women having HS versus
laparoscopic TL as the dependent variable, and the covariates in the
PSM included age (18–24 [reference], 25–29, 30–34, 35–39, 40–44,
45–49); race (White [reference], African American, Hispanic, other
race, unknown); Charlson Comorbidity Index (CCI) score (0 [reference]
or ≥1); geographic region (North East [reference], South, Midwest,
West, other); comorbidities (hypertension, asthma, hypothyroidism,
diabetes, obesity); pelvic pain-related conditions (ﬁbroid, benign ovarian neoplasms); prior pregnancy/delivery (during the 6-month baseline
but beyond 6 weeks prior to the index date); and oral contraceptive or
injectable methods used during a 6-month baseline prior to index. Logistic regressions were also conducted using the unmatched population
to compare the risk of hysterectomy, CPP and AUB 24 months post-HS
versus laparoscopic TL by controlling patient demographic and clinical
characteristics. All statistical analyses were carried out using SAS 9.3.
3. Results
3.1. Patient characteristics
Overall, 14,804 women met the inclusion criteria and had at least
24 months of continuous data poststerilization; 3929 had undergone
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24 months of continuous data poststerilization; 3929 had undergone
HS, and 10,875 had undergone laparoscopic TL (Supplementary Fig. 2
and Table 1). At baseline, women in the HS cohort were older than in
the laparoscopic TL cohort (mean [SD] age 31.8 [6.1] vs. 30.4 [5.9]
years, respectively; pb.0001). Fewer women in the laparoscopic TL

The primary outcomes measures were the proportion of women
who underwent hysterectomy and were diagnosed with CPP or diagnosed with AUB at 6, 12 and 24 months post index event. Hysterectomy
was identiﬁed based on CPT codes, and the latter two outcomes were
430
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identiﬁ ed using International Classi ﬁcation of Diseases, Ninth Revision

7.7%; pb.0001), diabetes (5.1% vs. 3.5%; pb.0001) or obesity (6.6% vs. 4.7%;
pb.0001). Fewer women in the HS group than those in the laparoscopic TL
group received a diagnosis code for a pain condition (chronic headache,
low back pain, pelvic pain, ﬁbromyalgia) (35.1% vs. 40.0%; pb.0001). Baseline AUB was higher in the HS group than in the laparoscopic TL group
(8.1% vs. 6.4%; p=.0004). Fewer women in the HS group used no prescription contraceptive during the baseline period (no contraceptive

than in the HS group had diagnosis codes for hypertension (10.2% vs.

use: 63.7% vs. 83.7%; pb.0001). The difference in contraceptive use was
most marked for oral contraceptives (8.8% in the HS group vs. 5.3% in
the laparoscopic TL group; pb.0001) and for injectables (25.1% in the HS
group vs. 7.5% in the laparoscopic TL group; pb.0001). There were also signiﬁcant differences in race/ethnicity, as shown in Table 1. PSM adjusted
baseline characteristics were similar between both groups except for inﬂammatory bowel disease and low back pain.

Table 1
Baseline demographics in the overall study population and the PSM adjusted population a.
Overall study population
HS
(n=3929)

Laparoscopic TL
(n=10,875)

p value

HS
(n=2673)

Laparoscopic TL
(n=2673)

p value

31.8 (6.1)

30.4 (5.9)

b.0001

−1.62, − 1.18

23.38

30.9 (5.6)

30.8 (5.7)

.3414

Age group, n (%)
18–20 years
21–24 years
25–29 years
30–34 years
35–39 years
40–44 years
45–49 years

3 (0.1)
447 (11.4)
1117 (28.4)
1107 (28.2)
775 (19.7)
369 (9.4)
111 (2.8)

8 (0.1)
1818 (16.7)
3571 (32.8)
2865 (26.3)
1658 (15.3)
783 (7.2)
172 (1.6)

.9561
b.0001
b.0001
.0265
b.0001
b.0001
b.0001

−0.10, 0.10
−6.56, −4.12
−6.07, −2.74
0.20, 3.46
3.06, 5.90
1.16, 3.23
0.67, 1.81

0.10
15.41
9.57
4.11
11.81
7.95
8.48

2 (0.1)
328 (12.3)
886 (33.2)
762 (28.5)
467 (17.5)
200 (7.5)
28 (1.1)

1 (0.04)
334 (12.5)
884 (33.1)
757 (28.3)
468 (17.5)
200 (7.5)
29 (1.1)

Race
White
African American
Hispanic
Other race
Unknown

2076 (52.8)
1152 (29.3)
496 (12.6)
96 (2.4)
109 (2.8)

6959 (64.0)
2225 (20.5)
1160 (10.7)
182 (1.7)
349 (3.2)

b.0001
b.0001
.4316
b.0001
.2706

−10.97, −7.34
7.57, 10.78
−1.05, 0.44
0.45, 1.51
−1.92, 0.53

18.52
21.48
1.47
7.10
2.06

1603 (60.0)
686 (25.7)
293 (11.0)
36 (1.4)
55 (2.1)

CCI score, n (%)
0
1–2
3–4
N4

3313 (84.3)
558 (14.2)
34 (0.9)
24 (0.6)

9252 (85.1)
1509 (13.9)
68 (0.6)
46 (0.4)

.2581
.6131
.1190
.1413

−2.07, 0.57
−0.94, 1.60
−0.09, 0.57
−0.08, 0.46

2.09
0.94
2.79
2.62

402 (10.2)
246 (6.3)
140 (3.6)
202 (5.1)
258 (6.6)
21 (0.5)
19 (0.5)
14 (0.4)

841 (7.7)
758 (7.0)
348 (3.2)
379 (3.5)
511 (4.7)
47 (0.4)
34 (0.3)
35 (0.3)

b.0001
.1298
.2744
b.0001
b.0001
.4163
.1241
.7470

1.43, 3.57
−1.61, 0.19
−0.30, 1.03
0.88, 2.43
1.00, 2.74
−0.16, 0.36
−0.07, 0.41
−0.18, 0.25

Comorbidities associated with pelvic pain, n (%)
Fibroid
67 (1.7)
Benign ovarian neoplasm
140 (3.6)
Endometriosis
19 (0.5)
Prolapse
13 (0.3)

125 (1.2)
420 (3.9)
84 (0.8)
51 (0.5)

.0083
.4001
.0619
.2581

Preexisting pain during baseline period, n (%)
Pelvic pain
880 (22.4)
Low back pain
485 (12.3)
Chronic headache
301 (7.7)
Fibromyalgia
82 (2.1)
Any form of pre-existing pain b
1378 (35.1)
AUB, n (%)
317 (8.1)
Prior pregnancy or delivery, c n (%) 1692 (43.1)

2792 (25.7)
1772 (16.3)
1014 (9.3)
248 (2.3)
4353 (40.0)
695 (6.4)
4793 (44.1)

Contraceptives used during baseline period, d n (%)
None
2502 (63.7) 9097 (83.7)
Oral contraceptive
347 (8.8)
572 (5.3)
Contraceptive patch
45 (1.2)
133 (1.2)
Vaginal ring
106 (2.7)
221 (2.0)
Implant
0 (0.0)
9 (0.1)
Intrauterine system
21(0.5)
71 (0.7)
Injectable
987 (25.1)
813 (7.5)

Mean (SD) age, years

Comorbidities, n (%)
Hypertension
Asthma
Hypothyroidism
Diabetes
Obesity
Rheumatoid arthritis
IBD
SLE

95%CI for
difference

PSM adjusted population
Effect
size

95%CI for
difference

Effect
size

−0.45, − 0.16

2.60

.5636
.8033
.9536
.8795
.9713
1.0000
.8941

−0.09, 0.16
−1.99, 1.54
−2.45, 2.60
−2.23, 2.61
−2.07, 2.00
−1.41, 1.41
−0.59, 0.51

1.58
0.68
0.16
0.41
0.10
0.00
0.36

1599 (60.0)
693 (25.9)
293 (11.0)
35 (1.3)
53 (2.0)

.9111
.8268
1.0000
.9049
.8458

−2.48, 2.78
−2.61, 2.08
−1.67, 1.67
−0.58, 0.65
−0.68, 0.83

0.31
0.60
0.00
0.33
0.53

2474 (92.6)
188 (7.0)
6 (0.2)
5 (0.2)

2477 (92.7)
185 (6.9)
5 (0.2)
6 (0.2)

.8754
.8721
.7628
.7628

−1.51, 1.29
−1.25, 1.48
−0.21, 0.28
−0.28, 0.21

0.43
0.44
0.83
0.83

8.74
2.85
2.01
8.16
8.11
1.47
2.71
0.59

111 (4.2)
97 (3.6)
39 (1.5)
47 (1.8)
65 (2.4)
9 (0.3)
14 (0.5)
0 (0.0)

116 (4.3)
99 (3.7)
37 (1.4)
50 (1.9)
66 (2.5)
3 (0.1)
5 (0.2)
2 (0.1)

.7345
.8843
.8173
.7585
.9295
.0829
.0386
.1572

−1.27, 0.89
−1.08, 0.93
−0.56, 0.71
−0.83, 0.60
−0.87, 0.79
−0.03, 0.48
0.02, 0.66
−0.18, 0.03

0.93
0.40
0.63
0.84
0.24
4.74
5.66
3.87

0.10, 1.01
−0.98, 0.38
−0.56, −0.02
−0.36, 0.08

4.69
1.58
3.66
2.19

4 (0.2)
44 (1.7)
10 (0.4)
9 (0.3)

5 (0.2)
44 (1.7)
11 (0.4)
9 (0.3)

.7387
1.0000
.8269
1.0000

−0.26, 0.18
−0.68, 0.68
−0.37, 0.30
−0.31, 0.31

0.91
0.00
0.60
0.00

b.0001
b.0001
.0017
.4815
b.0001
.0004
.2745

−4.82, −1.74
−5.19, −2.71
− 2.66, −0.67
−0.72, 0.33
−6.71, −3.20
0.71, 2.65
−2.82, 0.80

7.67
11.29
5.97
1.32
10.24
6.48
2.04

522 (19.5)
294 (11.0)
185 (6.9)
42 (1.6)
830 (31.1)
101 (3.8)
1159 (41.9)

505 (18.9)
344 (12.9)
187 (7.0)
42 (1.6)
830 (31.1)
101 (3.8)
1154 (41.9)

.5551
.0349
.9144
1.0000
1.0000
1.0000
.8902

−1.48, 2.75
−3.61, − 0.13
−1.44, 1.29
−0.67, 0.67
−2.48, 2.48
−1.02, 1.02
−2.47, 2.84

1.61
5.77
0.29
0.00
0.00
0.00
0.38

b.0001
b.0001
.7019
.0150
.0713
.4183
b.0001

−21.63, −18.31
2.59, 4.55
−0.47, 0.31
0.09, 1.24
−0.14, − 0.03
−0.39, 0.16
16.20, 19.09

46.55
13.99
0.72
4.38
4.07
1.54
49.19

2042 (76.4)
145 (5.4)
35 (1.3)
75 (2.8)
0 (0.0)
15 (0.6)
378 (14.1)

2043 (76.4)
145 (5.4)
35 (1.3)
63 (2.4)
1 (0.04)
20 (0.8)
376 (14.1)

.9743
1.0000
1.0000
.3007
.3173
.3965
.9374

−2.31, 2.24
−1.21, 1.21
−0.61, 0.61
−0.40, 1.30
−0.11, 0.04
−0.62, 0.25
−1.79, 1.94

0.09
0.00
0.00
2.83
2.74
2.32
0.21

Note: Values in italics indicate those meeting the criteria for statistical (p value).
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Note: Values in italics indicate those meeting the criteria for statistical (p value).
IBD, inﬂammatory bowel disease; SLE, systemic lupus erythematosus.
a
Only 35 states available in the 2012 MAX data at time of analysis: AK, AL, AR, CT, DE, FL, GA, IA, IL, IN, KY, MD, MI, MN, MO, MS, MT, NC, NE, NJ, NV, NY, OH, OK, OR, PA, SC, SD, TN, TX, VA,
VT, WA, WV and WY.
b
Included pelvic pain, low back pain, chronic headache or ﬁbromyalgia.
c
Six weeks or more before index date.
d
R. Steward et al. / Contraception 97 (2018) 428–433
431
Within the 6 months prior to the index date.

3.2. Contraceptive use in the overall study population
“No use” of prescription contraceptives poststerilization (2 weeks
preindex to 3 months postindex) was signiﬁcantly higher in the laparoscopic TL group compared to the HS group (97.0% vs. 77.2%; pb.0001, respectively). The difference in contraceptive use poststerilization was
most marked for oral contraceptives (HS, 6.4% vs. laparoscopic TL,
1.5%; pb.0001) and for injectables (HS, 14.5% vs. laparoscopic TL
group, 0.8%; pb.0001).
3.3. Overall population
In an unmatched analysis, poststerilization hysterectomy and a diagnosis of CPP after sterilization were signiﬁcantly more common in the
laparoscopic TL group than the HS group both at 12 months and
24 months (pb.005 for all) (Table 2). The rates of AUB diagnoses after
sterilization procedure were signiﬁcantly more common in the HS
group than the laparoscopic TL group at 12 months (p=.0059) but not
at 24 months (p=.3145) (Table 2).
3.4. Postmatching analysis
At 6 months, there were no signiﬁcant differences between the laparoscopic TL group and the HS group in the rates of poststerilization
hysterectomy, diagnosis of CPP or diagnosis of AUB (Table 3). Hysterectomy was signiﬁcantly more common in the laparoscopic TL group than
the HS group at 24 months (3.5% vs. 2.1%; p=.0023). A diagnosis of CPP
after sterilization was signiﬁcantly more common in the laparoscopic TL
group than the HS group at 12 months (13.8% vs. 11.7%; p=.0215) and
24 months (26.8% vs. 23.5%; p=.0050). There were no signiﬁcant differences in the rates of AUB diagnoses after sterilization procedure at
12 months (p=.4334) and 24 months (p=.7629).
3.5. Logistic regression analysis
Logistic regression identiﬁed HS as being associated with a lower
risk of hysterectomy (odds ratio [OR] 0.77 [95% CI 0.60–0.97]; p=
.0274) or a CPP diagnosis (OR 0.91 [95% CI 0.83 –0.99]; p=.0336) in
the 24 months poststerilization; there was a similar risk of AUB compared to laparoscopic TL (Table 4).
4. Discussion
Both unmatched and PSM analyses of Medicaid patients indicate
that pelvic pain and AUB are common in women before and after sterilization whether the procedure is performed hysteroscopically or
Table 2
Descriptive outcomes of women in the TL cohort and HS cohort during the 24-months
follow-up period (unmatched)
HS
(N=3929)
n (%)

Laparoscopic
TL (N=10,875)
n (%)

6-Month outcomes
Hysterectomy
17 (0.4)
77 (0.7)
Chronic pelvic pain
215 (5.5)
737 (6.8)
AUB
88 (2.2)
131 (1.2)
12-Month outcomes
Hysterectomy
39 (1.0)
190 (1.8)
Chronic pelvic pain
517 (13.2) 1789 (16.5)
AUB
189 (4.8)
413 (3.8)
24-Month outcomes

p value

95% CI for
difference

Effect
size

.0625
.0043
b.0001

−0.53,−0.02 3.66
−2.16,−0.45 5.44
0.53,1.54
7.96

.0010
b.0001
.0059

−1.15,−0.36 6.49
−4.56,−2.03 9.28
0.25,1.77
4.99

Table 3
PSM adjusted descriptive outcomes of women in the TL cohort and HS cohort during the
24-months follow-up period
HS
(N=2673)
n (%)
6-Month outcomes
Hysterectomy
10 (0.4)
Chronic pelvic pain 127 (4.8)
AUB
44 (1.7)
12-Month outcomes
Hysterectomy
25 (0.9)
Chronic pelvic pain 312 (11.7)
AUB
108 (4.04)
24-Month outcomes
Hysterectomy
57 (2.1)
Chronic pelvic pain 628 (23.5)
AUB
212 (7.9)

Laparoscopic
TL (N=2673)
n (%)

p value

95% CI for
difference

Effect
size

16 (0.6)
139 (5.2)
40 (1.5)

.2382
.4504
.6600

−0.60, 0.15
−1.61, 0.72
−0.52, 0.82

3.23
2.06
1.20

36 (1.4)
368 (13.8)
97 (3.6)

.1566
.0215
.4334

−0.98, 0.16
−3.88, −0.31
−0.62, 1.44

3.87
6.29
2.14

94 (3.5)
717 (26.8)
218 (8.2)

.0023
.0050
.7629

−2.27, −0.50
−5.65, −1.00
−1.68, 1.23

8.36
7.68
0.83

Note: Values in italics indicate those meeting the criteria for statistical signiﬁcance
(p value).

laparoscopically. Moreover, HS is associated with a signiﬁcantly lower
risk of hysterectomy at 24 months or a CPP diagnosis at 12 and
24 months poststerilization when compared to TL, consistent with earlier reports [3]. Higher rates of AUB were found in the unmatched comparison at 6 and 12 months but not at 24 months; there were no
differences in AUB at any time point in the matched analysis.
Consistent with previous reports [8], the publicly insured women in
our study underwent sterilization at an average age of about 30 years
compared to a mean age of about 37 years for commercially insured
women. [3,8]. Consistent with our data, a comparison of Medicaid and
commercially insured women undergoing HS or TL found that the Medicaid cohort was more likely to be using an injectable contraceptive and
less likely to be using an oral contraceptive prior to sterilization [8].
Medicaid patients had a higher mean CCI score and were more likely
to be obese or to have asthma than commercially insured women but
less likely to have hypothyroidism [8].
Previous researchers found a signiﬁcant difference in the rate of AUB
during the ﬁrst year following HS versus TL [3]. This potentially may be
explained by the need to continue contraception after HS until a conﬁrmation test has demonstrated proper insert location. Therefore, in the
ﬁrst several months after HS, women are still experiencing the effects of
taking, then withdrawing from, hormonal contraception, whereas
women undergoing TL can cease using contraceptives immediately after
sterilization. In our matched analysis, however, the rate of AUB was similar at 6, 12 and 24 months postprocedure (Table 3). Logistic regression
analysis in our study cohort identiﬁed baseline obesity, race (African
American, Hispanic, other), pain condition, AUB and the use of injectable
contraceptives as risk factors for an AUB diagnosis after sterilization.
Reports have emerged about pain developing after HS [5,9,10], but
until recently, the studies comparing outcomes after HS and TL were limited by their deﬁnitions of pain (e.g., severe pain requiring opioids) [4] or
by their short duration of follow-up [11]. In using a deﬁnition of pain that
was consistent with previous research [3], we found a higher rate of CPP
diagnosis after sterilization in patients who underwent TL compared with
those who underwent HS (26.8% vs. 23.5%). While the rate of CPP was signiﬁcantly higher in the TL versus the HS group in this study, the difference
is small and unlikely to represent a clinically important difference. Nevertheless, the data from this study are consistent with Perkins et al. in that
HS is not associated with more CPP than is TL [3].
These data are an important adjunct to previous database analyses,
which have used data from employer-based insurance plans [3] and excluded Medicaid or Medicare patients. According to the Women's
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Hysterectomy
Chronic pelvic
pain
AUB

97 (2.5)
1010 (25.7)

382 (3.5)
3223 (29.6)

366 (9.3)

955 (8.8)

.0015
b.0001
.3145

−1.64,−0.45 6.13
−5.54,−2.32 8.79
−0.52,1.59

1.86

5/8/18, 3(27 AM

cluded Medicaid or Medicare patients. According to the Women's
Health 2013 report, about two thirds of women aged 18 to 64 years
(67.3%) have private health insurance [12], while 13.2% rely on public
insurance. Therefore, although our data set is representative of only a
small proportion of US women, it is a cohort in whom outcomes after

Note: Values in italics indicate those meeting the criteria for statistical signiﬁcance (p
432
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value).
sterilization have

not been previously studied in detail.

Table 4
Logistic regression analysis examining the OR of having different outcomes at 24 months based on type of sterilization procedure and baseline characteristics.
Hysterectomy
OR (95%CI)

Pelvic pain
p value

OR (95% CI)

AUB
p value

OR (95% CI)

p value

Procedure
Laparoscopic TL (ref)
HS

0.77 (0.60, 0.97)

.0274

0.91 (0.83, 0.99)

.0336

1.06 (0.93, 1.21)

.3967

Age
18–24 years (ref)
25–29 years
30–34 years
35–39 years
40–44 years
45–49 years

1.17 (0.89, 1.54)
0.99 (0.73, 1.33)
0.97 (0.69, 1.37)
1.00 (0.66, 1.53)
1.04 (0.53, 2.05)

.2603
.9413
.8731
.9871
.9126

0.76 (0.68, 0.84)
0.53 (0.47, 0.59)
0.49 (0.43, 0.56)
0.42 (0.36, 0.50)
0.47 (0.35, 0.63)

b.0001
b.0001
b.0001
b.0001
b.0001

0.93 (0.78, 1.10)
0.93 (0.78, 1.12)
0.81 (0.66, 1.00)
1.09 (0.86, 1.40)
0.86 (0.56, 1.33)

.3934
.4611
.0545
.4776
.5033

Race
White (reference)
African American
Hispanic
Other Race
Unknown

0.41 (0.31, 0.55)
0.46 (0.31, 0.69)
0.36 (0.13, 0.98)
0.78 (0.45, 1.36)

b.0001
.0002
.0449
.3792

0.74 (0.67, 0.81)
1.01 (0.89, 1.15)
0.56 (0.41, 0.77)
0.96 (0.77, 1.19)

b.0001
.8999
.0004
.7133

0.72 (0.62, 0.84)
0.66 (0.53, 0.82)
0.61 (0.37, 0.99)
0.79 (0.56, 1.13)

b.0001
.0001
.0463
.1961

Geographic region
Northeast (ref)
South
Midwest
West
Unknown

1.26 (0.97,1.66)
0.88 (0.67,1.17)
1.25 (0.80,1.94)
2.12 (1.34, 3.34)

.0895
.3849
.3219
.0013

0.98 (0.87, 1.09)
0.98 (0.88, 1.09)
1.25 (1.04, 1.51)
1.23 (0.98, 1.53)

.6533
.6879
.0178
.0717

0.90 (0.77, 1.06)
0.84 (0.71, 0.98)
1.13 (0.86, 1.49)
0.93 (0.66, 1.31)

.2158
.0291
.3888
.6823

CCI score
0 (ref)
≥1

1.31 (0.93, 1.85)

.1291

1.31 (1.12, 1.53)

.0008

1.24 (0.99, 1.56)

.0615

Comorbidity
Hypertension
Asthma
Hypothyroidism
Diabetes
Obesity

1.16 (0.84, 1.60)
0.95 (0.61, 1.47)
0.81 (0.48, 1.35)
0.90 (0.53, 1.52)
0.65 (0.40, 1.06)

.3769
.8141
.4113
.6939
.0871

1.21 (1.05, 1.38)
1.14 (0.94, 1.38)
1.13 (0.93, 1.39)
1.04 (0.83, 1.31)
1.16 (0.98, 1.36)

.0064
.1901
.2244
.7124
.0841

1.20 (0.99, 1.46)
1.01 (0.76, 1.33)
1.22 (0.92, 1.62)
1.09 (0.79, 1.49)
1.28 (1.02, 1.62)

.0702
.9744
.1705
.6133
.0373

Pelvic pain-related conditions
Fibroid
Benign ovarian neoplasms
Baseline pain
Baseline AUB
Prior pregnancy or delivery a

1.65 (0.86, 3.15)
2.33 (1.70, 3.19)
1.95 (1.60, 2.37)
2.03 (1.55, 2.66)
0.94 (0.77, 1.15)

.1309
b.0001
b.0001
b.0001
.5465

1.09 (0.79, 1.52)
2.06 (1.72, 2.47)
2.59 (2.40, 2.80)
1.40 (1.22, 1.62)
0.87 (0.80, 0.94)

.6023
b.0001
b.0001
b.0001
.0005

1.38 (0.90, 2.11)
1.19 (0.92, 1.53)
1.66 (1.48, 1.87)
2.21 (1.86, 2.64)
0.99 (0.87, 1.11)

.1375
.1881
b.0001
b.0001
.8114

Prior contraceptive use b
Oral contraceptives
Injectable contraceptives

0.99 (0.67, 1.47)
1.25 (0.94, 1.67)

.9507
.1202

1.08 (0.92, 1.26)
1.11 (0.99, 1.25)

.3408
.0724

1.15 (0.92, 1.45)
1.30 (1.10, 1.54)

.2262
.0025

Note: Values in italics indicate those meeting the criteria for statistical signiﬁcance (p value).
a
Six weeks or more before index date.
b
Within the 6 months prior to the index date.

Database analyses have limitations. The comorbidities and diagnoses
used are based solely on ICD-9 or CPT codes, and there is potential for coding errors to occur during data entry. The MAX database has 2012 data for
only 35 states; however, the data come from all regions of the United
States and are therefore likely to be nationally representative. MAX ﬁles
contain only Medicaid-paid services and do not capture service use or expenditures during periods of nonenrollment, services paid by other
payers or services provided at no charge. This database consists of claims
submitted by healthcare providers to insurance companies for reimbursement on behalf of individuals, probably contributing to underreporting of
AUB and pelvic pain events as many patients experience these conditions
without consulting a healthcare professional [13,14]. In addition, other
limitations may be associated with claims data use because data are collected for the purpose of payment and not research. Comorbidities and diagnoses were based solely on ICD-9 or CPT codes. Operationalization of

A strength of our analysis was the exclusion of women who had concomitant gynecologic procedures on the index sterilization date that
could have an impact on the study outcome measures. Because many
of these procedures are more likely to be performed in one study cohort
than the other (eg, lysis of adhesions will only be performed in the laparoscopic group), allowing these additionally treated subjects to remain
in the analysis would create an uncontrollable bias. An additional
strength of our analysis is the use of the propensity score model,
which included all measured baseline covariates potentially associated
with treatment assignment and outcomes.
In conclusion, our data demonstrate that the incidence of hysterectomy and CPP in publicly insured women is lower after HS compared
to after TL. In propensity score matched analyses, HS is associated
with lower odds of having a hysterectomy at 24 months or receiving a
diagnosis of CPP at 12 and 24 months, but not 6 months, after steriliza-
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agnoses were based solely on ICD-9 or CPT codes. Operationalization of
concepts, such as CPP and AUB, must rely on the frequency of the codes
reported as clinical records are not available. In addition, other variables,
such as level of education and socioeconomic status, are known to affect
reports of chronic pelvic pain, AUB and hysterectomy [15]. It is unknown

diagnosis of CPP at 12 and 24 months, but not 6 months, after sterilization compared to TL. The clinical relevance of these ﬁndings is uncertain
given the small absolute difference in rates. The incidence rates of AUB
at 6, 12 and 24 months poststerilization were similar in women who
underwent HS compared to TL (Table 3). Logistic regression analyses

R. Steward et al. / Contraception 97 (2018) 428–433

how unmeasured variables such as these would affect these analyses.

Supplementary data to this article can be found online at https://doi.
org/10.1016/j.contraception.2017.12.015.
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